Novo Nordisk Dirección

Dirección controles de criterios 4/4

El CEO de Novo Nordisk's es Lars Jorgensen , nombrado en Jan 2017, tiene una permanencia de 7.25 años. compensación anual total es DKK60.10M, compuesta por 28.5% salario y 71.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.002% de las acciones de la empresa, por valor de $11.60M. La antigüedad media del equipo directivo y de la junta directiva es de 3.2 años y 6.1 años, respectivamente.

Información clave

Lars Jorgensen

Chief Executive Officer (CEO)

kr.60.1m

Compensación total

Porcentaje del salario del CEO	28.5%
Permanencia del CEO	7.3yrs
Participación del CEO	0.002%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	6.1yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Novo Nordisk: Dominating In Diabetes And Obesity

Jun 05

Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity

May 23

Novo Nordisk: Attractive Market But Likely No Margin Of Safety

Feb 15

Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg

Feb 07

Novo Nordisk FY 2022 Earnings Preview

Jan 31

Novo Nordisk says FDA updated label for oral diabetes therapy Rybelsus

Jan 13

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lars Jorgensen en comparación con los beneficios de Novo Nordisk?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	kr.84b
Sep 30 2023	n/a	n/a	kr.75b
Jun 30 2023	n/a	n/a	kr.67b
Mar 31 2023	n/a	n/a	kr.61b
Dec 31 2022	kr.60m	kr.17m	kr.56b
Sep 30 2022	n/a	n/a	kr.53b
Jun 30 2022	n/a	n/a	kr.51b
Mar 31 2022	n/a	n/a	kr.49b
Dec 31 2021	kr.58m	kr.17m	kr.48b
Sep 30 2021	n/a	n/a	kr.46b
Jun 30 2021	n/a	n/a	kr.44b
Mar 31 2021	n/a	n/a	kr.43b
Dec 31 2020	kr.57m	kr.14m	kr.42b
Sep 30 2020	n/a	n/a	kr.42b
Jun 30 2020	n/a	n/a	kr.41b
Mar 31 2020	n/a	n/a	kr.40b
Dec 31 2019	kr.55m	kr.14m	kr.39b
Sep 30 2019	n/a	n/a	kr.39b
Jun 30 2019	n/a	n/a	kr.38b
Mar 31 2019	n/a	n/a	kr.38b
Dec 31 2018	kr.41m	kr.11m	kr.39b
Sep 30 2018	n/a	n/a	kr.38b
Jun 30 2018	n/a	n/a	kr.39b
Mar 31 2018	n/a	n/a	kr.39b
Dec 31 2017	kr.32m	kr.9m	kr.38b

Compensación vs. Mercado: La compensación total de Lars($USD8.62M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Lars ha sido consistente con los resultados de la empresa en el último año.

CEO

Lars Jorgensen (57 yo)

7.3yrs

Permanencia

kr.60,100,000

Compensación

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lars Jorgensen	President	7.3yrs	kr.60.10m	0.0021% DKK 11.8m
Karsten Knudsen	Executive VP	6.2yrs	kr.21.50m	0.000010% DKK 56.7k
Henrik Wulff	Executive VP of Product Supply	no data	kr.22.00m	0.000060% DKK 340.4k
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	kr.21.30m	0% DKK 0
Martin Lange	Executive VP of Development & Member of the Management Board	3.3yrs	kr.20.90m	sin datos
Marcus Schindler	EVP of Research & Early Development	3.1yrs	kr.20.90m	sin datos
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	sin datos	0.0024% DKK 13.4m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	sin datos	sin datos
Ludovic Helfgott	Executive VP	no data	sin datos	sin datos
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.1yrs	sin datos	sin datos
David Moore	Executive VP of Corporate Development & Member of Management Board	1.1yrs	sin datos	sin datos
Daniel Bohsen	CVP & Head of Investor Relations	no data	sin datos	sin datos

3.2yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVO se considera experimentado (3.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sylvie Gregoire	Independent Director	9.1yrs	kr.1.80m	sin datos
Helge Lund	Independent Chairman of the Board	7.1yrs	kr.3.10m	sin datos
Henrik Poulsen	Vice Chairman of the Board	3.1yrs	kr.2.00m	sin datos
Laurence Debroux	Independent Director	5.1yrs	kr.2.00m	sin datos
Martin MacKay	Independent Director	6.1yrs	kr.1.70m	sin datos
Andreas Fibig	Independent Director	6.1yrs	kr.1.40m	sin datos
Kasim Kutay	Non-Independent Director	7.1yrs	kr.1.20m	sin datos
Christina Law	Independent Director	2.1yrs	kr.1.30m	sin datos
Liselotte Hyveled	Employee Representative Director	2.1yrs	kr.800.00k	0.00019% DKK 1.1m
Mette Jensen	Employee Non-Independent Representative Director	6.1yrs	kr.1.20m	sin datos
Thomas Rantzau	Employee Representative Non-Independent Director	6.3yrs	kr.1.00m	sin datos
Elisabeth Christensen	Employee Representative Director	2.1yrs	kr.800.00k	sin datos

6.1yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NVO se considera experimentada (6.1 años de antigüedad promedio).

Novo Nordisk Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Recent updates

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Novo Nordisk: The Moat Won't Last Forever

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Novo Nordisk, A Very Healthy Pharma Stalwart

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Taking Novo Nordisk To The Next Level

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk: Denmark's Coca-Cola

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk: Dominating In Diabetes And Obesity

Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

Novo Nordisk: Attractive Market But Likely No Margin Of Safety

Heartseed and Novo Nordisk A/S Announces First Patient Dosed in Clinical Study with HS-001 – A Cell Therapy Designed to Restore Heart Function in People with Advanced Heart Failure

Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 28,000 million worth of its shares.

Novo Nordisk FY 2022 Earnings Preview

Novo Nordisk Announces FDA Approval of Label Update for Rybelsus® (Semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes

Novo Nordisk says FDA updated label for oral diabetes therapy Rybelsus

Novo Nordisk A/S to Report First Half, 2023 Results on Aug 10, 2023

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad